Akcea Therapeutics, a late-stage biotech developing therapies for rare lipid disorders, raised $125 million by offering 15.6 million shares at $8, below the range of $12 to $14. It added 6.0 million shares to the offering to keep the deal size unchanged. Akcea Therapeutics plans to list on the Nasdaq under the symbol AKCA. Cowen & Company, Stifel and Wells Fargo Securities acted as lead managers on the deal.
